| Dr Brian K Griffith, MD | |
|
4522 Maccorkle Ave Se, Charleston, WV 25304-1840 | |
| (304) 982-8246 | |
| (304) 345-1801 |
| Full Name | Dr Brian K Griffith |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 25 Years |
| Location | 4522 Maccorkle Ave Se, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437199056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | WV21067 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Charleston Surgical Hospital | Charleston, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Virginia Eye Consultants Llc | 2062689524 | 11 |
News Archive
The coronavirus disease (COVID-19) pandemic is rippling across the globe, with over 27.47 million reported cases. With the vast spread of the virus, scientists are racing to gain the approval of candidate vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease and Multisystem Inflammatory Syndrome in Children (MIS-C).
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.
Infants are listening and learning their first words as young as 10 months, but they are only learning the words for objects that are of interest to them, not for objects of interest to the speaker, according to researchers at Temple University, University of Delaware and University of Evansville.
In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.
› Verified 6 days ago
| Entity Name | West Virginia Eye Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801171517 PECOS PAC ID: 2062689524 Enrollment ID: O20120124000593 |
News Archive
The coronavirus disease (COVID-19) pandemic is rippling across the globe, with over 27.47 million reported cases. With the vast spread of the virus, scientists are racing to gain the approval of candidate vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease and Multisystem Inflammatory Syndrome in Children (MIS-C).
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.
Infants are listening and learning their first words as young as 10 months, but they are only learning the words for objects that are of interest to them, not for objects of interest to the speaker, according to researchers at Temple University, University of Delaware and University of Evansville.
In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian K Griffith, MD 501 Summers St, Charleston, WV 25301-1239 Ph: (304) 343-3937 | Dr Brian K Griffith, MD 4522 Maccorkle Ave Se, Charleston, WV 25304-1840 Ph: (304) 982-8246 |
News Archive
The coronavirus disease (COVID-19) pandemic is rippling across the globe, with over 27.47 million reported cases. With the vast spread of the virus, scientists are racing to gain the approval of candidate vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease and Multisystem Inflammatory Syndrome in Children (MIS-C).
Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.
Infants are listening and learning their first words as young as 10 months, but they are only learning the words for objects that are of interest to them, not for objects of interest to the speaker, according to researchers at Temple University, University of Delaware and University of Evansville.
In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.
› Verified 6 days ago
Dr. Paul Frederick Francke, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E Ste 203, Charleston, WV 25301 Phone: 304-343-4124 Fax: 304-343-4167 | |
Dr. Huseyin Kadikoy, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E, Charleston, WV 25301 Phone: 304-388-6630 Fax: 304-388-6629 | |
Dr. Stephen Paul Cassis, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 301 49th St Se, Suite A, Charleston, WV 25304 Phone: 304-925-3937 Fax: 304-925-4336 | |
Dr. Audrey Lilian Hunt, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1220 Lee St E, Charleston, WV 25301 Phone: 304-388-6630 Fax: 304-388-6629 | |
Richard Mark Hatfield, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 331 Laidley St, Ste 301, Charleston, WV 25301 Phone: 304-346-4400 Fax: 304-346-0704 | |
James White Caudill, MD RETIRED Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 501 Summers St, Charleston, WV 25301 Phone: 304-343-3937 Fax: 304-344-3957 | |
Dr. Sara E O'connor, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1306 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-343-4371 Fax: 304-353-0215 |